Natco Pharma rated 'Buy' Q1 shows better than expected ... India was down 20% y-o-y due to GST but management expects recovery in Q2FY18. ... of significant FDA issues makes it one of the best placed Indian pharma companies.
Read more: Natco Pharma rated 'Buy' Q1 shows better than expected